ArticleEuropean cytokine network2026
VEGFC as a prognostic cytokine biomarker linking lymph node metastasis to immune suppression in breast cancer.
Article in European cytokine network, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundsLymph node metastasis is a critical determinant of breast cancer prognosis, yet the specific microenvironmental cytokines driving this process remain elusive. This study aims to identify key prognostic cytokines linking nodal metastasis to tumor microenvironment (TME) remodeling and to evaluate their clinical utility.
methodsA predefined panel of 176 microenvironmental genes was evaluated using differential expression analysis and the Least Absolute Shrinkage and Selection Operator (LASSO) algorithm on the TCGA-BRCA cohort to identify optimal predictors of nodal metastasis. Prognostic value was assessed via Kaplan-Meier, subgroup, and multivariate Cox regression analyses, and validated across five independent GEO datasets. Immune infiltration and therapeutic potential were evaluated using Gene Set Enrichment Analysis (GSEA), CIBERSORT deconvolution, pharmacogenomic screening, and molecular docking simulations.
resultsVascular Endothelial Growth Factor C (VEGFC) emerged as the top biomarker significantly upregulated in node-positive tumors. Multivariate analysis confirmed that VEGFC acts as a robust, independent predictor of poor relapse-free survival (RFS). Notably, subgroup analyses revealed this prognostic penalty is exceptionally pronounced in hormone receptor-positive Luminal A and B subtypes. Mechanistically, elevated VEGFC is strongly associated with an immunosuppressive "cold" TME, characterized by reduced cytotoxic CD8+ T-cell infiltration and enriched M2-macrophage polarization across multiple algorithms. Furthermore, pharmacogenomic analyses and docking simulations indicated potential sensitivity to PI3K/AKT inhibitors in VEGFC-high tumors.
conclusionsVEGFC is a robust, independent precision biomarker specifically indicating poor prognosis in Luminal breast cancers. It is significantly associated with an immune-excluded TME, suggesting that targeting the VEGFC axis may offer a novel strategy to reverse immune evasion.
Indexed as
Identifiers
42421501What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.